AstraZeneca's Enhertu Receives FDA Approval for HER-2 Positive Tumor-Agnostic Indications
Friday, 5 April 2024, 20:14
AstraZeneca's Enhertu Receives FDA Approval
The FDA has granted approval to AstraZeneca's Enhertu for the treatment of specific metastatic tumors, making it the first antibody drug conjugate to receive a tumor-agnostic indication.
Significant Industry Milestone
This approval marks a notable milestone in the pharmaceutical industry as it advances precision medicine for cancer treatment.
- Revolutionary Treatment: Enhertu offers a new approach for HER-2 positive cancers.
- First Tumor-Agnostic Indication: Setting a new standard for personalized cancer therapies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.